Recombinant Shiga toxin B subunit can induce neutralizing immunoglobulin y antibody

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 6, 2012, Pages 917-923

  Neri, Paola ^a   Tokoro, Shunji ^a   Sugiyama, Tsuyoshi ^a   Umeda, Kouji ^b   Shimizu, Takeshi ^c   Tsuji, Takao ^d   Kodama, Yoshikatsu ^b,e   Mori, Hiroshi ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b Immunology Research Institute   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Immunology Research Institute   (Japan)

Author keywords

Chicken; Immunoglobulin Y; Neutralizing antibody; Shiga toxin B subunit; Shiga toxin mediated disease

Indexed keywords

IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN Y ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT SHIGA TOXIN 1 B SUBUNIT; RECOMBINANT SHIGA TOXIN 2 B SUBUNIT; SHIGA TOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHICKEN; CONTROLLED STUDY; CROSS REACTION; EGG YOLK; HELA CELL; NONHUMAN;

EID: 84861875878     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.917     Document Type: Article

References (37)

1. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxinproducing Escherichia coli infections. Clin. Microbiol. Rev., 11, 450-479 (1998).
2. Lingwood CA, Law H, Richardson S, Petric M, Brunton JL, De Grandis S, Karmali M. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J. Biol. Chem., 262, 8834-8839 (1987).
3. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem., 171, 45-50 (1988).
4. Mulvey GL, Marcato P, Kitov PI, Sadowska J, Bundle DR, Armstrong GD. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J. Infect. Dis., 187, 640-649 (2003).
5. Watanabe M, Matsuoka K, Kita E, Igai K, Higashi N, Miyagawa A, Watanabe T, Yanoshita R, Samejima Y, Terunuma D, Natori Y, Nishikawa K. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J. Infect. Dis., 189, 360-368 (2004).
6. Neri P, Tokoro S, Yokoyama S, Miura T, Murata T, Nishida Y, Kajimoto T, Tsujino S, Inazu T, Usui T, Mori H. Monovalent Gb3-/Gb2- derivatives conjugated with a phosphatidyl residue: a novel class of Shiga toxin-neutralizing agent. Biol. Pharm. Bull., 30, 1697-1701 (2007).
7. Yamagami S, Motoki M, Kimura T, Izumi H, Takeda T, Katsuura Y, Matsumoto Y. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J. Infect. Dis., 184, 738-742 (2001).
8. Dowling TC, Chavaillaz PA, Young DG, Melton-Celsa A, O'Brien A, Thuning-Roberson C, Edelman R, Tacket CO. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. Antimicrob. Agents Chemother., 49, 1808-1812 (2005).
9. Sheoran AS, Chapman-Bonofiglio S, Harvey BR, Mukherjee J, Georgiou G, Donohue-Rolfe A, Tzipori S. Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect. Immun., 73, 4607-4613 (2005).
10. López EL, Contrini MM, Glatstein E, González Ayala S, Santoro R, Allende D, Ezcurra G, Teplitz E, Koyama T, Matsumoto Y, Sato H, Sakai K, Hoshide S, Komoriya K, Morita T, Harning R, Brookman S. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob. Agents Chemother., 54, 239-243 (2010).
11. Reilly RM, Domingo R, Sandhu J. Oral delivery of antibodies. Future pharmacokinetic trends. Clin. Pharmacokinet., 32, 313-323 (1997).
12. Sarker SA, Casswall TH, Juneja LR, Hoq E, Hossain I, Fuchs GJ, Hammarström L. Randomized, placebo-controlled, clinical trial of hyperimmunized chicken egg yolk immunoglobulin in children with rotavirus diarrhea. J. Pediatr. Gastroenterol. Nutr., 32, 19-25 (2001).
13. Shin JH, Yang M, Nam SW, Kim JT, Myung NH, Bang WG, Roe IH. Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection. Clin. Diagn. Lab. Immunol., 9, 1061-1066 (2002).
14. Amaral JA, De Franco MT, Zapata-Quintanilla L, Carbonare SB. In vitro reactivity and growth inhibition of EPEC serotype O111 and STEC serotypes O111 and O157 by homologous and heterologous chicken egg yolk antibody. Vet. Res. Commun., 32, 281-290 (2008).
15. Neri P, Tokoro S, Kobayashi R, Sugiyama T, Umeda K, Shimizu T, Tsuji T, Kodama Y, Oguma K, Mori H. Specific egg yolk immunoglobulin as a new preventive approach for Shiga-toxin-mediated diseases. PLoS ONE, 6, e26526 (2011).
16. Shimizu T, Kawakami S, Sato T, Sasaki T, Higashide M, Hamabata T, Ohta T, Noda M. The serine 31 residue of the B subunit of Shiga toxin 2 is essential for secretion in enterohemorrhagic Escherichia coli. Infect. Immun., 75, 2189-2200 (2007).
17. Tsuji T, Shimizu T, Sasaki K, Tsukamoto K, Arimitsu H, Ochi S, Shimizu T, Taniguchi K, Noda M, Neri P, Mori H. A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2. Vaccine, 26, 2092-2099 (2008).
18. Mori H, Natarajan K, Betschart B, Weiss N, Franklin RM. Polyclonal B-cell activation and autoantibody formation during the course of mosquito-transmitted Plasmodium berghei infection in mice. Trop. Med. Parasitol., 38, 157-162 (1987).
19. Nagano K, Sugisaki T, Taguchi K, Hara T, Naiki M, Mori H. A murine model of enterohemorrhagic Escherichia coli O157:H7 infection to assess immunopotentiating activity of drugs on mucosal immunity: effect of drugs. J. Pharmacol. Sci., 91, 219-228 (2003).
20. Neri P, Nagano SI, Yokoyama S, Dohi H, Kobayashi K, Miura T, Inazu T, Sugiyama T, Nishida Y, Mori H. Neutralizing activity of polyvalent Gb3, Gb2 and galacto-trehalose models against Shiga toxins. Microbiol. Immunol., 51, 581-592 (2007).
21. Donohue-Rolfe A, Jacewicz M, Keusch GT. Isolation and characterization of functional Shiga toxin subunits and renatured holotoxin. Mol. Microbiol., 3, 1231-1236 (1989).
22. Mine Y, Kovacs-Nolan J. Chicken egg yolk antibodies as therapeutics in enteric infectious disease: a review. J. Med. Food, 5, 159-169 (2002).
23. Yokoyama H, Umeda K, Peralta RC, Hashi T, Icatlo FC Jr, Kuroki M, Ikemori Y, Kodama Y. Oral passive immunization against experimental salmonellosis in mice using chicken egg yolk antibodies specific for Salmonella enteritidis and S. typhimurium. Vaccine, 16, 388-393 (1998).
24. Amaral JA, Tino De Franco M, Carneiro-Sampaio MM, Carbonare SB. Anti-enteropathogenic Escherichia coli immunoglobulin Y isolated from eggs laid by immunised Leghorn chickens. Res. Vet. Sci., 72, 229-234 (2002).
25. Cook SR, Bach SJ, Stevenson SML, Devinney R, Frohlich AA, Fang L, Mcallister TA. Orally administered anti-Escherichia coli O157:H7 chicken egg yolk antibodies reduce fecal shedding of the pathogen by ruminants. Can. J. Anim. Sci., 85, 291-299 (2005).
26. Girard F, Batisson I, Martinez G, Breton C, Harel J, Fairbrother JM. Use of virulence factor-specific egg yolk-derived immunoglobulins as a promising alternative to antibiotics for prevention of attaching and effacing Escherichia coli infections. FEMS Immunol. Med. Microbiol., 46, 340-350 (2006).
27. Acheson DW, De Breucker SA, Jacewicz M, Lincicome LL, Donohue- Rolfe A, Kane AV, Keusch GT. Expression and purification of Shiga-like toxin II B subunits. Infect. Immun., 63, 301-308 (1995).
28. Byun Y, Ohmura M, Fujihashi K, Yamamoto S, McGhee JR, Udaka S, Kiyono H, Takeda Y, Kohsaka T, Yuki Y. Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies. Vaccine, 19, 2061-2070 (2001).
29. Jackson MP, Neill RJ, O'brien AD, Holmes RK, Newland JW. Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from Escherichia coli 933. FEMS Microbiol. Lett., 44, 109-114 (1987).
30. Calderwood SB, Acheson DWK, Goldberg MB, Boyko SA, Donohue- Rolfe A. A system for production and rapid purification of large amounts of the Shiga toxin/Shiga-like toxin I B subunit. Infect. Immun., 58, 2977-2982 (1990).
31. Head SC, Karmali MA, Lingwood CA. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. J. Biol. Chem., 266, 3617-3621 (1991).
32. Kitova EN, Daneshfar R, Marcato P, Mulvey GL, Armstrong G, Klassen JS. Stability of the homopentameric B subunits of Shiga toxins 1 and 2 in solution and the gas phase as revealed by nanoelectrospray fourier transform ion cyclotron resonance mass spectrometry. J. Am. Soc. Mass Spectrom., 16, 1957-1968 (2005).
33. Krautz-Peterson G, Chapman-Bonofiglio S, Boisvert K, Feng H, Herman IM, Tzipori S, Sheoran AS. Intracellular neutralization of Shiga toxin 2 by an a subunit-specific human monoclonal antibody. Infect. Immun., 76, 1931-1939 (2008).
34. Strockbine NA, Marques LR, Newland JW, Smith HW, Holmes RK, O'Brien AD. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect. Immun., 53, 135-140 (1986).
35. Downes FP, Barrett TJ, Green JH, Aloisio CH, Spika JS, Strockbine NA, Wachsmuth IK. Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies. Infect. Immun., 56, 1926-1933 (1988).
36. Wang Q, Hou XJ, Cai K, Li T, Liu YN, Tu W, Xiao L, Bao SZ, Shi J, Gao X, Liu H, Tian RM, Wang H. Passive protection of purified yolk immunoglobulin administered against Shiga toxin 1 in mouse models. Can. J. Microbiol., 56, 1003-1010 (2010).
37. Parma YR, Chacana PA, Rogé A, Kahl A, Cangelosi A, Geoghegan P, Lucchesi PMA, Fernández-Miyakawa ME. Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: isolation, purification and neutralization efficacy. Toxicon, 58, 380-388 (2011).